Literature DB >> 22622365

CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.

Alessandro Stefani1, Livia Brusa, Enrica Olivola, Mariangela Pierantozzi, Alessandro Martorana.   

Abstract

Dementia has become a relevant problem associated with the elderly in our countries. Increased interest in the field has yielded a copious literature, so far mostly centered on Alzheimer's dementia. Cerebrospinal fluid (CSF) analysis combined with neuropsychology, even in absence of neuroimaging, represents the gold standard to reach a diagnosis when cortical cognitive impairment prevails. In view of this, low levels of CSF amyloid peptides β (Aβ) and high tau/Aβ protein ratio, despite prominent impairment of executive functions or concomitant vascular burden, facilitate the diagnosis of Alzheimer's disease. Conversely, an early cognitive impairment occurring in patients suffering from Parkinson's disease (PD) or Lewy body disorders (LBDs), both diagnoses posed on pure clinical grounds, remains quite elusive in term of biomarkers or neuropsychological assessment. Whether PD with dementia (PDD) and dementia with Lewy bodies (DLB) represent further steps along with a continuum of the same progressive degeneration due to Lewy bodies deposition, rather then the association of Lewy bodies and Aβ pathology, remains a challenging issue. Aim of this work is to set a state-of-the-art on the neuropsychological profiles of both or DLB. Then, we will focus on the ongoing controversies about the specificity of the standard CSF biomarkers if applied to extrapyramidal disorders. Our conclusions are that the CSF pattern, in PDD and DLB, can certainly be distinct from that in AD, though mechanisms leading to dementia could be shared among them. It is possible that, by combining imaging tracers, neuropsychologically careful assessment and renewed CSF biomarkers, DLB can be better distinguished in subgroups, depending on the presence or absence of a relevant amyloid burden. However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622365     DOI: 10.1007/s00702-012-0820-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  96 in total

1.  Multimodality imaging characteristics of dementia with Lewy bodies.

Authors:  Kejal Kantarci; Val J Lowe; Bradley F Boeve; Stephen D Weigand; Matthew L Senjem; Scott A Przybelski; Dennis W Dickson; Joseph E Parisi; David S Knopman; Glenn E Smith; Tanis J Ferman; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2011-10-21       Impact factor: 4.673

2.  L-dopa modulates motor cortex excitability in Alzheimer's disease patients.

Authors:  Alessandro Martorana; Alessandro Stefani; Maria Giuseppina Palmieri; Zaira Esposito; Giorgio Bernardi; Giuseppe Sancesario; Mariangela Pierantozzi
Journal:  J Neural Transm (Vienna)       Date:  2008-07-02       Impact factor: 3.575

3.  The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia.

Authors:  M Andersson; H Zetterberg; L Minthon; K Blennow; E Londos
Journal:  Int J Geriatr Psychiatry       Date:  2011-01       Impact factor: 3.485

4.  Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

Authors:  Brit Mollenhauer; Lukas Cepek; Mirko Bibl; Jens Wiltfang; Walter J Schulz-Schaeffer; Barbara Ciesielczyk; Manuela Neumann; Petra Steinacker; Hans A Kretzschmar; Sigrid Poser; Claudia Trenkwalder; Markus Otto
Journal:  Dement Geriatr Cogn Disord       Date:  2005-01-05       Impact factor: 2.959

5.  Specific neuromodulatory actions of amyloid-beta on dopamine release in rat nucleus accumbens and caudate putamen.

Authors:  Elisa Mura; Stefania Preda; Stefano Govoni; Cristina Lanni; Luigia Trabace; Massimo Grilli; Federica Lagomarsino; Anna Pittaluga; Mario Marchi
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  Dopaminergic function and progression of Parkinson's disease: PET findings.

Authors:  G Biju; R de la Fuente-Fernández
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

Review 7.  Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease.

Authors:  Satyabrata Kar; Stephen P M Slowikowski; David Westaway; Howard T J Mount
Journal:  J Psychiatry Neurosci       Date:  2004-11       Impact factor: 6.186

8.  Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases.

Authors:  B Pillon; B Deweer; Y Agid; B Dubois
Journal:  Arch Neurol       Date:  1993-04

9.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

Authors:  A E van der Vlies; N A Verwey; F H Bouwman; M A Blankenstein; M Klein; P Scheltens; W M van der Flier
Journal:  Neurology       Date:  2009-03-24       Impact factor: 9.910

View more
  5 in total

Review 1.  The spectrum of cognitive impairment in Lewy body diseases.

Authors:  Jennifer G Goldman; Caroline Williams-Gray; Roger A Barker; John E Duda; James E Galvin
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

2.  Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.

Authors:  Niklas K U Koehler; Elke Stransky; Mona Shing; Susanne Gaertner; Mirjam Meyer; Brigitte Schreitmüller; Thomas Leyhe; Christoph Laske; Walter Maetzler; Phillipp Kahle; Maria S Celej; Thomas M Jovin; Andreas J Fallgatter; Anil Batra; Gerhard Buchkremer; Klaus Schott; Elke Richartz-Salzburger
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 3.  Catecholamine-Based Treatment in AD Patients: Expectations and Delusions.

Authors:  Alessandro Stefani; Enrica Olivola; Claudio Liguori; Atticus H Hainsworth; Valentina Saviozzi; Giacoma Angileri; Vincenza D'Angelo; Salvatore Galati; Mariangela Pierantozzi
Journal:  Front Aging Neurosci       Date:  2015-05-04       Impact factor: 5.750

4.  Serotonin impairment in CSF of PD patients, without an apparent clinical counterpart.

Authors:  Enrica Olivola; Mariangela Pierantozzi; Paola Imbriani; Claudio Liguori; Mario Stampanoni Bassi; Marco Conti; Vincenza D'Angelo; Nicola Biagio Mercuri; Alessandro Stefani
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

5.  Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia.

Authors:  Orestes V Forlenza; Marcia Radanovic; Leda L Talib; Ivan Aprahamian; Breno S Diniz; Henrik Zetterberg; Wagner F Gattaz
Journal:  Alzheimers Dement (Amst)       Date:  2015-10-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.